TABLE 1.

Yearly use of glycopeptides for animals and humans in the United States and some European countries

Yr	Glycopeptide usage (kg of active substance)/yr
	Vancomycin used for humans (oral and injectable)a		Avoparcin used for animalsb (oral)
	U.S.	Europec	Denmark
1984	2,000	303	NAd
1985	2,600	413	NA
1986	3,700	461	NA
1987	5,000	579	NA
1988	6,000	756	NA
1989	7,600	1,251	13,644
1990	8,299	1,257	13,718
1991	9,794	1,515	23,153
1992	10,690	1,666	17,210
1993	11,364	1,954	19,572
1994	11,460	2,256	24,117
1995	11,279	2,528	5,690e
1996	11,200	2,858	0

^aData on human glycopeptide use are from reference 5. 

^bData on use of avoparcin as a growth promoter for pigs, broilers, and turkeys are from the Danish Plant Directorate. 

^cFrance, Germany, Italy, United Kingdom, and The Netherlands. 

^dNA, data not available; avoparcin was approved for use in Denmark in 1974. 

^eAvoparcin was banned in May 1995 in Denmark. The use was voluntarily suspended by the swine producers in April 1995.